Neoadjuvant nivolumab plus ipilimumab in surgically resectable hepatocellular carcinoma (PRIME-HCC): a prospective, phase 1b, single-arm trial and translational analyses
Elsevier ·
The publisher did not provide an abstract — full text is available via the link below.
Neoadjuvant nivolumab plus ipilimumab in surgically resectable hepatocellular carcinoma (PRIME-HCC): a prospective, phase 1b, single-arm trial and translational analyses. // The Lancet Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S1470204526003311?dgcid=rss_sd_all
Neoadjuvant nivolumab plus ipilimumab in surgically resectable hepatocellular carcinoma (PRIME-HCC): a prospective, phase 1b, single-arm trial and translational analyses. The Lancet Oncology. https://www.sciencedirect.com/science/article/pii/S1470204526003311?dgcid=rss_sd_all
“Neoadjuvant nivolumab plus ipilimumab in surgically resectable hepatocellular carcinoma (PRIME-HCC): a prospective, phase 1b, single-arm trial and translational analyses.” The Lancet Oncology.
@article{article98526,
title = {Neoadjuvant nivolumab plus ipilimumab in surgically resectable hepatocellular carcinoma (PRIME-HCC): a prospective, phase 1b, single-arm trial and translational analyses},
journal = {The Lancet Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S1470204526003311?dgcid=rss_sd_all}
}